AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14555373 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 1155
Study 14555373 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomach ache
Number of subjects: 1155
Study 14555373 — intervention group
Group type: EXPERIMENTAL
Intervention: Backache
Number of subjects: 1155
Study 10541927 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal treadmill exercise at 7, 8, and 9 km/h for 4 minutes at 0800, 1300, and 1700 hours.
Number of subjects: 21
Study 8727528 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 10
Study 8727528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11188584 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 41
Study 11188584 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies Depression scale (CES-D)
Number of subjects: 41
Study 11188584 — intervention group
Group type: EXPERIMENTAL
Intervention: General Well-Being Schedule depression subscale (GWB-D)
Number of subjects: 41
Study 11188584 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (57 age-matched)
Number of subjects: 41
Study 7048880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg
Number of subjects: 131
Study 7048880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 131
Study 7048880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 60 mg
Number of subjects: 131
Study 7048880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (mean dose 50 mg/day)
Number of subjects: 131
Study 7048880 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (mean 360 mg/day)
Number of subjects: 131
Study 7048880 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (mean 107 mg/day)
Number of subjects: 131
Study 7048880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 31393146 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) delivered by JPOs
Number of subjects: 0
Study 31393146 — intervention group
Group type: COMPARATOR
Intervention: Probation services as usual (PAU)
Number of subjects: 0
Study 31148589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary micronutrient intakes
Number of subjects: 6426
Study 28633170 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based module outlining genetic concepts applied to CRC
Number of subjects: 60
Study 28633170 — intervention group
Group type: EXPERIMENTAL
Intervention: Live presentation of the web-based material
Number of subjects: 60
Study 28633170 — intervention group
Group type: EXPERIMENTAL
Intervention: Live presentation and subsequent standardized patient (SP) encounter
Number of subjects: 60
Study 28633170 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study 26070699 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 87
Study 26070699 — intervention group
Group type: COMPARATOR
Intervention: NPH (Neutral Protamine Hagedorn)
Number of subjects: 87
Study 23711593 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 0
Study 23711593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Number of subjects: 0
Study 23711593 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol and Mitiglinide combination
Number of subjects: 0
Study 19823804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (RTD)
Number of subjects: 9
Study 19823804 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 9
Study 19848210 — intervention group
Group type: EXPERIMENTAL
Intervention: Flos Magnoliae volatile oil nano-liposome nasal drops (FMO)
Number of subjects: 191
Study 19848210 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 191
Study 17531698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity UVA irradiation
Number of subjects: 30
Study 17531698 — intervention group
Group type: COMPARATOR
Intervention: Mechanical polishing
Number of subjects: 30
Study 17531698 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 17531698 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 15042308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff Pressure Control (Tracoe) device; target pressure of 25.5 cmH(2)O
Number of subjects: 80
Study 15042308 — intervention group
Group type: COMPARATOR
Intervention: Conventional handheld manometer; pressures kept between 20 cmH(2)O and 40 cmH(2)O
Number of subjects: 80
Study 15042308 — intervention group
Group type: COMPARATOR
Intervention: Both groups (automatic and conventional)
Number of subjects: 80
Study 11535206 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/LNG 20/100
Number of subjects: 767
Study 11535206 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/NET 20/500
Number of subjects: 767
Study 11535206 — intervention group
Group type: COMPARATOR
Intervention: EE/LNG 30/150
Number of subjects: 767
Study 9784769 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic epoetin alfa therapy
Number of subjects: 50
Study 9784769 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusions
Number of subjects: 50
Study 8068601 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE ε2 allele
Number of subjects: 574
Study 8068601 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE ε4 allele
Number of subjects: 574
Study 8068601 — intervention group
Group type: COMPARATOR
Intervention: ApoE E3/3 phenotype
Number of subjects: 574
Study 8068601 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ε2 allele
Number of subjects: 574
Study 8068601 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ε4 allele
Number of subjects: 574
Study 3073077 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 10
Study 3073077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg three times/day)
Number of subjects: 10
Study 3073077 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) plus Nifedipine (10 mg three times/day)
Number of subjects: 10
Study 3073077 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Nifedipine
Number of subjects: 10
Study 3073077 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Atenolol
Number of subjects: 10
Study 31269116 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐EWBT + three‐step etch‐and‐rinse (Scotchbond Multi Purpose, 3M ESPE)
Number of subjects: 148
Study 31269116 — intervention group
Group type: EXPERIMENTAL
Intervention: EWBT + Scotchbond Multi Purpose (MP)
Number of subjects: 148
Study 31269116 — intervention group
Group type: EXPERIMENTAL
Intervention: EWBT + Bond (third step of MP)
Number of subjects: 148
Study 31269116 — intervention group
Group type: EXPERIMENTAL
Intervention: EWBT + universal adhesive (Single Bond Universal, 3M ESPE)
Number of subjects: 148
Study 27879326 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 131
Study 27879326 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group B)
Number of subjects: 131
Study 27879326 — intervention group
Group type: COMPARATOR
Intervention: TPOAb-negative group (Control Group C)
Number of subjects: 131
Study 26679186 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face instructor-led program
Number of subjects: 60
Study 26679186 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid program with alternating face-to-face and mobile technology-delivered content
Number of subjects: 60
Study 26679186 — intervention group
Group type: COMPARATOR
Intervention: Both intervention formats combined
Number of subjects: 60
Study 26679186 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face vs hybrid format
Number of subjects: 60
Study 23224142 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-enriched enteral nutrition (AeEN)
Number of subjects: 20
Study 23224142 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing enteral nutrition (IeEN)
Number of subjects: 20
Study 21510896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 132
Study 21510896 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 132
Study 21510896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CT and PRT
Number of subjects: 132
Study 21510896 — intervention group
Group type: COMPARATOR
Intervention: Sham interventions (educational videos and seated calisthenics)
Number of subjects: 132
Study 19065862 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiracial faces given European names
Number of subjects: 0
Study 19065862 — intervention group
Group type: COMPARATOR
Intervention: Multiracial faces given Asian names
Number of subjects: 0
Study 16781360 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide + reduced dose unfractionated heparin (n = 298)
Number of subjects: 857
Study 16781360 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide + reduced-dose enoxaparin (n = 275)
Number of subjects: 857
Study 16781360 — intervention group
Group type: COMPARATOR
Intervention: bivalirudin monotherapy (n = 284)
Number of subjects: 857
Study 16781360 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 857
Study 14586603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitative treatment for 14 days
Number of subjects: 60
Study 14586603 — intervention group
Group type: COMPARATOR
Intervention: Ordinary rehabilitative treatment for 14 days
Number of subjects: 60
Study 11056254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG)
Number of subjects: 46
Study 11056254 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy (OHS)
Number of subjects: 46
Study 11056254 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion hysterosonography (SIS)
Number of subjects: 46
Study 11056254 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG) and Outpatient hysteroscopy (OHS)
Number of subjects: 46
Study 11056254 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG) and Saline infusion hysterosonography (SIS)
Number of subjects: 46
Study 11056254 — intervention group
Group type: COMPARATOR
Intervention: Outpatient hysteroscopy (OHS) and Saline infusion hysterosonography (SIS)
Number of subjects: 46
Study 8816211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant (cumulative phospholipid dose of 200 mg/kg)
Number of subjects: 40
Study 8816211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant (single dose of 100 mg/kg)
Number of subjects: 40
Study 8816211 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (17 infants)
Number of subjects: 40
Study 1409770 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation (10 mg, 100 mg, 1000 mg, 10,000 mg EPA daily; 3 mg, 33 mg, 333 mg, 3333 mg DHA)
Number of subjects: 0
Study 1409770 — intervention group
Group type: COMPARATOR
Intervention: Olive oil as placebo
Number of subjects: 0
Study 2934264 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 0
Study 2934264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 2934264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30891808 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression
Number of subjects: 1981
Study 30891808 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 1981
Study 27400939 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA-ATO
Number of subjects: 276
Study 27400939 — intervention group
Group type: COMPARATOR
Intervention: ATRA-CHT
Number of subjects: 276
Study 26327799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative ibuprofen 400 mg
Number of subjects: 0
Study 26327799 — intervention group
Group type: COMPARATOR
Intervention: Early post-operative ibuprofen 400 mg
Number of subjects: 0
Study 25674254 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (uploading blood glucose and metabolic information at home every 2 weeks, with a follow-up interval of 3 months)
Number of subjects: 114
Study 25674254 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 114
Study 25674254 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face visit (control group)
Number of subjects: 114
Study 20832196 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed antiretroviral therapy (DOT)
Number of subjects: 77
Study 20832196 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy (Control)
Number of subjects: 77
Study 19018794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC)
Number of subjects: 40
Study 19018794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TAC and 5-fluorouracil (5-FU)
Number of subjects: 40
Study 19018794 — intervention group
Group type: COMPARATOR
Intervention: Control group (TAC)
Number of subjects: 40
Study 17463116 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee replacement
Number of subjects: 26
Study 17463116 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 26
Study 15220172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway insertion
Number of subjects: 24
Study 15220172 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal airway insertion
Number of subjects: 24
Study 15220172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 11782640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ACL deficient patients
Number of subjects: 81
Study 11782640 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstructed patients
Number of subjects: 81
Study 11782640 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 81
Study 11782640 — intervention group
Group type: COMPARATOR
Intervention: Acute ACL deficient subjects
Number of subjects: 81
Study 9793664 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-N2O anaesthesia during upper abdominal surgery
Number of subjects: 30
Study 9793664 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-N2O anaesthesia
Number of subjects: 30
Study 9793664 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-N2O-fentanyl anaesthesia
Number of subjects: 30
Study 9793664 — intervention group
Group type: COMPARATOR
Intervention: Control (prostaglandin E1 before surgical incision)
Number of subjects: 30
Study 8291119 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ cell-depleted bone marrow
Number of subjects: 38
Study 8291119 — intervention group
Group type: COMPARATOR
Intervention: Unmodified bone marrow (Control)
Number of subjects: 38
Study 15904653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 37
Study 15904653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 37
Study 15904653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ramipril and Telmisartan
Number of subjects: 37
Study 31759587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 47
Study 31759587 — intervention group
Group type: EXPERIMENTAL
Intervention: Whipped cream
Number of subjects: 47
Study 31759587 — intervention group
Group type: COMPARATOR
Intervention: Sour cream
Number of subjects: 47
Study 30658932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096
Study 30658932 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study 28934792 — intervention group
Group type: EXPERIMENTAL
Intervention: CCPRF
Number of subjects: 43
Study 28934792 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF
Number of subjects: 43
Study 28934792 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 43
Study 25220488 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Exercise Program (HEP)
Number of subjects: 390
Study 25220488 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 390
Study 23130675 — intervention group
Group type: EXPERIMENTAL
Intervention: T+5-HT(1A)ra
Number of subjects: 54
Study 23130675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23130675 — intervention group
Group type: COMPARATOR
Intervention: T+PDE5i
Number of subjects: 54
Study 20947917 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-head CPR
Number of subjects: 102
Study 20947917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral CPR
Number of subjects: 102
Study 20947917 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating CPR
Number of subjects: 102
Study 18555224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Endometrin 100 mg twice a day, n = 12; Endometrin 100 mg three times a day, n = 11; Crinone 8% gel 90 mg every day, n = 17)
Number of subjects: 240
Study 18555224 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) progesterone (50 mg every day, n = 200)
Number of subjects: 240
Study 18555224 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) progesterone
Number of subjects: 240
Study 18555224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 240
Study 18555224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal and IM progesterone
Number of subjects: 240
Study 17214405 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg/day for 21 days)
Number of subjects: 20
Study 17214405 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 20
Study 17214405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose tablets)
Number of subjects: 20
Study 12766655 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasacral approach with 20 ml ropivacaine, 0.75% (single bolus)
Number of subjects: 150
Study 12766655 — intervention group
Group type: EXPERIMENTAL
Intervention: Winnie's single injection approach with 20 ml ropivacaine, 0.75% (single bolus)
Number of subjects: 150
Study 12766655 — intervention group
Group type: EXPERIMENTAL
Intervention: Winnie's double injection approach with 20 ml ropivacaine, 0.75% (10 ml plus 10 ml)
Number of subjects: 150
Study 10660713 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous coated Osteonic 7000 tibial component (Group 1)
Number of subjects: 60
Study 10660713 — intervention group
Group type: COMPARATOR
Intervention: Standard saw blade with the same tibial component as Group 1 (Group 2)
Number of subjects: 60
Study 10660713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated Osteonic tibial component (Group 3)
Number of subjects: 60
Study 10660713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite Duracon tibial component (Group 4)
Number of subjects: 60
Study 9249622 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with visual hallucinations (VH)
Number of subjects: 29
Study 9249622 — intervention group
Group type: COMPARATOR
Intervention: Patients without visual hallucinations (Control)
Number of subjects: 29
Study 8262828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) at a dose of 25 Gy
Number of subjects: 62
Study 8262828 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative radiotherapy (IORT) at a dose of 20 Gy or less
Number of subjects: 62
Study 8262828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of IORT and modified total esophagectomy
Number of subjects: 62
Study 3553433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg (t.i.d.)
Number of subjects: 10
Study 3553433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (t.i.d.)
Number of subjects: 10
Study 3553433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (t.i.d.)
Number of subjects: 10
Study 29522132 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence among IG predators in experimental plots of maize and soybean.
Number of subjects: 0
Study 29522132 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence among aphid predators on tansy (using published data).
Number of subjects: 0
Study 27504925 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate computerized brief intervention
Number of subjects: 80
Study 27504925 — intervention group
Group type: COMPARATOR
Intervention: Delayed computerized brief intervention
Number of subjects: 80
Study 24636210 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily
Number of subjects: 497
Study 24636210 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 497
Study 24636210 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily (T-scores < -2.0)
Number of subjects: 497
Study 24636210 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily (T-scores < -2.0)
Number of subjects: 497
Study 23142059 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone
Number of subjects: 512
Study 20404221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg daily
Number of subjects: 10
Study 20404221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20404221 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg daily
Number of subjects: 10
Study 18317680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough bread (leavened for 8 hours with autochthonous Saccharomyces cerevisiae and bacilli)
Number of subjects: 16
Study 18317680 — intervention group
Group type: COMPARATOR
Intervention: Reference bread (leavened for 2 hours with commercial baker yeast)
Number of subjects: 16
Study 15990081 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% fixed combination (Trav/Tim)
Number of subjects: 263
Study 15990081 — intervention group
Group type: COMPARATOR
Intervention: Travoprost 0.004% (Trav)
Number of subjects: 263
Study 15990081 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (Tim)
Number of subjects: 263
Study 12612224 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 80
Study 12612224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80